Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids

Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

1 . A method of treating or preventing atherosclerosis in a subject having a high baseline serum glucose level of at least 126 mg/dL and a baseline triglyceride level of at least 500 mg/dL, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof and further comprising determining a baseline oxidized sdLDL level in the subject prior to administering to the subject the pharmaceutical composition. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition comprises at least 80%, at least 90%, at least 95%, or at least 96%, by weight of all fatty acids (and/or derivatives thereof) present, eicosapentaenoic acid or a derivative thereof. 
     
     
         3 . The method of  claim 1 , wherein the pharmaceutical composition comprises no docosahexaenoic acid or esters thereof. 
     
     
         4 . The method of  claim 1 , wherein the reduction or prevention occurs by a free radical chain-breaking mechanism. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 1 , further comprising determining a second oxidized sdLDL level in the subject after administering to the subject the pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof, wherein the second oxidized sdLDL level is not greater than, not significantly greater than, or lower than the baseline oxidized sdLDL level and/or wherein the second oxidized sdLDL level is not greater than, not significantly greater than, or lower than the baseline oxidized sdLDL level in comparison to a second subject who has not received the pharmaceutical composition. 
     
     
         7 . The method of  claim 6 , wherein the method further comprises administering atorvastatin and/or o-hydroxyatorvastatin to the subject. 
     
     
         8 . The method of  claim 7 , wherein the second oxidized sdLDL level is not greater than, not significantly greater than, or lower than the baseline oxidized sdLDL level in comparison to a second subject who has received the atorvastatin and/or the o-hydroxyatorvastatin but not the pharmaceutical composition. 
     
     
         9 . The method of  claim 7 , wherein the second oxidized sdLDL level is not greater than, not significantly greater than, or lower than the baseline oxidized sdLDL level in comparison to a second subject who has received the pharmaceutical composition but not the o-hydroxyatorvastatin. 
     
     
         10 . The method of  claim 1 , wherein the subject is on statin therapy, optionally stable statin therapy. 
     
     
         11 . The method of  claim 1 , wherein the subject is diabetic. 
     
     
         12 . The method of  claim 1 , wherein the high baseline serum glucose level is a fasting serum glucose level of at least 160 mg/dL. 
     
     
         13 . The method of  claim 1 , wherein the high baseline serum glucose level is a non-fasting serum glucose level of at least 200 mg/dL.